<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=896170837107954&amp;ev=PageView&amp;noscript=1">

NeoTract Announces Independent Analysis in UK Confirming Cost Effectiveness of UroLift® System Treatment for Benign Prostatic Hyperplasia (BPH)

WAYNE, PA – June 08, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the results of an independent analysis measuring costs and patient outcomes of the UroLift System compared to transurethral resection of the prostate (TURP). The study demonstrated that replacing the current standard of care for men suffering symptoms of benign prostatic hyperplasia (BPH) with the UroLift® System could save the National Health System approximately (NHS) £27 million in costs associated with post-surgical complications.

Read More

NeoTract Announces American Urological Association (AUA) Recommendation of UroLift® System as a Standard of Care Option for the Treatment of Enlarged Prostate

PLEASANTON, Calif. – May 18, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE: TFX) focused on addressing unmet needs in the field of urology, today announced that the American Urological Association (AUA) has recommended the use of the UroLift® System as a standard of care treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).

Read More

NeoTract To Unveil New Clinical Data on the UroLift® System at American Urological Association 2018 Meeting

PLEASANTON, Calif. - May 16, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced a series of presentations planned for the 113th Annual Meeting of the American Urological Association (AUA) taking place May 18 - 21 in San Francisco.

Read More

NeoTract Announces Data from Large Real-World Study of UroLift® System, Confirming Positive Results for Company’s Treatment for Enlarged Prostate

PLEASANTON, Calif. – March 19, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE: TFX) focused on addressing unmet needs in the field of urology, today announced the results from the first analysis of a retrospective registry of more than 800 UroLift® System procedures performed at seven centers in North America, Europe and Australia.

Read More

Teleflex Incorporated Completes Acquisition of Neotract

Teleflex

Contact:
Jake Elguicze
Treasurer and Vice President of Investor Relations
610-948-2836

Read More

Teleflex Incorporated to Acquire NeoTract

FOR IMMEDIATE RELEASE September 5, 2017

Read More

NeoTract Inc. Announces Cigna Coverage for the UroLift® System for Enlarged Prostate

PLEASANTON, Calif.– May 11, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that Cigna, a global health service company that provides insurance for over 14 million Americans, has established coverage for the UroLift® System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH).

Read More

NeoTract Inc. Announces Presentations of Multiple Clinical Studies Featuring Five-Year Data from Pivotal Randomized Trial of UroLift® System at American Urological Association 2017 Meeting

PLEASANTON, Calif.– May 8, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced activities planned for the 112th American Urological Association Annual Meeting taking place May 12-16 at the Boston Convention and Exhibition Center in Boston, Mass.

Read More

NeoTract Inc. Receives #Gamechanger Award for Innovation

PLEASANTON, Calif.– April 13, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the company has been recognized with the Innovation Tri-Valley Leadership Group’s #Gamechanger Award.

Read More

NeoTract’s Minimally Invasive UroLift® System for Enlarged Prostate Now Shown to be Durable Through Five Years: Results from Pivotal L.I.F.T. Randomized Study Presented

PLEASANTON, Calif. and LONDON – March 27, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced five-year follow-up data from the pivotal, randomized L.I.F.T. IDE study, which evaluated the safety and effectiveness of the company’s novel UroLift® System in patients with symptomatic benign prostatic hyperplasia (BPH).

Read More